Envoy Medical appoints Charles McKhann as Class I director and to Compensation Committee

Envoy Medical, Inc.

Board size increased from 6 to 7 members; McKhann appointed to Compensation Committee.
Awarded stock options for 100,000 shares at $0.72/share, vesting monthly over 36 months.
McKhann previously CEO of Silk Road Medical (acquired by Boston Scientific) and Apollo Endosurgery (also acquired by Boston Scientific).
McKhann is independent under Nasdaq listing standards and SEC rules.
Appointment effective April 15, 2026; term expires at 2027 annual meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.